307 related articles for article (PubMed ID: 33640225)
1. The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy.
Lenis AT; Fero KE; Ojeaburu L; Lec PM; Golla V; Brisbane W; Leapman MS; Chamie K
Urol Oncol; 2021 Aug; 39(8):496.e17-496.e24. PubMed ID: 33640225
[TBL] [Abstract][Full Text] [Related]
2. Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy.
von Landenberg N; Speed JM; Cole AP; Seisen T; Lipsitz SR; Gild P; Menon M; Kibel AS; Roghmann F; Noldus J; Sun M; Trinh QD
Urol Oncol; 2018 Feb; 36(2):78.e13-78.e19. PubMed ID: 29169845
[TBL] [Abstract][Full Text] [Related]
3. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.
Audenet F; Sfakianos JP; Waingankar N; Ruel NH; Galsky MD; Yuh BE; Gin GE
Urol Oncol; 2019 Feb; 37(2):116-122. PubMed ID: 30509868
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
[TBL] [Abstract][Full Text] [Related]
5. Induction Chemotherapy Followed by Surgery Versus Upfront Radical Cystectomy in Patients With Clinically Node-positive Muscle-invasive Bladder Cancer.
Pak S; You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Kim CS; Ahn H
Clin Genitourin Cancer; 2019 Jun; 17(3):e420-e428. PubMed ID: 30713014
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
[TBL] [Abstract][Full Text] [Related]
7. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
Gschwend JE; Heck MM; Lehmann J; Rübben H; Albers P; Wolff JM; Frohneberg D; de Geeter P; Heidenreich A; Kälble T; Stöckle M; Schnöller T; Stenzl A; Müller M; Truss M; Roth S; Liehr UB; Leißner J; Bregenzer T; Retz M
Eur Urol; 2019 Apr; 75(4):604-611. PubMed ID: 30337060
[TBL] [Abstract][Full Text] [Related]
8. Delays in radical cystectomy for muscle-invasive bladder cancer.
Chu AT; Holt SK; Wright JL; Ramos JD; Grivas P; Yu EY; Gore JL
Cancer; 2019 Jun; 125(12):2011-2017. PubMed ID: 30840335
[TBL] [Abstract][Full Text] [Related]
9. The Role of Lymph Node Dissection in Patients With Muscle-Invasive Bladder Cancer Who Underwent Radical Cystectomy Following Neoadjuvant Chemotherapy.
Zennami K; Takahara K; Nukaya T; Takenaka M; Ichino M; Sasaki H; Kusaka M; Sumitomo M; Shiroki R
Clin Genitourin Cancer; 2024 Apr; 22(2):1-9. PubMed ID: 37423863
[TBL] [Abstract][Full Text] [Related]
10. The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group.
Gild P; Vetterlein MW; Seiler R; Necchi A; Hendricksen K; Mertens LS; Roghmann F; Landenberg NV; Gontero P; Cumberbatch M; Dobruch J; Seisen T; Grande P; D'Andrea D; Anract J; Comploj E; Pycha A; Saba K; Poyet C; van Rhijn BW; Noon AP; Roupret M; Shariat SF; Fisch M; Xylinas E; Rink M
Surg Oncol; 2020 Sep; 34():312-317. PubMed ID: 32891350
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer.
Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y
Med Oncol; 2014 May; 31(5):949. PubMed ID: 24700028
[TBL] [Abstract][Full Text] [Related]
12. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.
Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554
[TBL] [Abstract][Full Text] [Related]
13. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
14. Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy.
Chalfin HJ; Liu JJ; Gandhi N; Feng Z; Johnson D; Netto GJ; Drake CG; Hahn NM; Schoenberg MP; Trock BJ; Scott AV; Frank SM; Bivalacqua TJ
Ann Surg Oncol; 2016 Aug; 23(8):2715-22. PubMed ID: 27012987
[TBL] [Abstract][Full Text] [Related]
15. Determinants of adequate lymph node dissection following neoadjuvant chemotherapy in patients with urothelial muscle-invasive bladder cancer: results from the National Cancer Database.
Monaghan TF; Flores VX; Suss NR; Robins DJ; Smith MT; McNeil BK; Hyacinthe LM; Weiss JP; Winer AG
Int Urol Nephrol; 2021 Feb; 53(2):235-239. PubMed ID: 32865771
[TBL] [Abstract][Full Text] [Related]
16. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM
JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780
[TBL] [Abstract][Full Text] [Related]
17. Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy.
Lee EK; Herr HW; Dickstein RJ; Kassouf W; Munsell MF; Grossman HB; Dinney CP; Kamat AM
BJU Int; 2012 Dec; 110(11 Pt B):E590-5. PubMed ID: 22758775
[TBL] [Abstract][Full Text] [Related]
18. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.
Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C
Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816
[TBL] [Abstract][Full Text] [Related]
19. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
20. Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy.
Alvaeus J; Rosenblatt R; Johansson M; Alamdari F; Jakubczyk T; Holmström B; Hemdan T; Huge Y; Aljabery F; Gabrielsson S; Riklund K; Winqvist O; Sherif A
World J Urol; 2020 Sep; 38(9):2207-2213. PubMed ID: 31760442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
